A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
for Chronic Graft-versus-host-disease
11 locations incl. Duarte
Sponsor: Incyte Corporation
Sex: All·Age: 2 - 17
Code: NCT07124078·Phase 2·Recruiting